Oxford Immunotec Global PLC (NASDAQ:OXFD) Earns Daily Coverage Optimism Score of 0.17
News stories about Oxford Immunotec Global PLC (NASDAQ:OXFD) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern rates the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Oxford Immunotec Global PLC earned a coverage optimism score of 0.17 on Accern’s scale. Accern also gave news headlines about the company an impact score of 46.0306593330903 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the headlines that may have effected Accern Sentiment’s scoring:
- Cowen and Company Lowers Oxford Immunotec Global PLC (OXFD) Price Target to $19.00 (americanbankingnews.com)
- Oxford Immunotec Global Plc breached its 50 day moving average in a Bearish Manner : OXFD-US : August 16, 2017 (finance.yahoo.com)
- Oxford Immunotec Global PLC (OXFD) COO Peter Edwardson Sells 9,739 Shares (americanbankingnews.com)
- Oxford Immunotec Global PLC : Announces Pricing of Underwritten Public Offering of Ordinary Shares (4-traders.com)
- Oxford Immunotec Global PLC Announces Pricing of Underwritten Public Offering of Ordinary Shares (finance.yahoo.com)
Shares of Oxford Immunotec Global PLC (OXFD) traded down 2.29% on Thursday, hitting $15.76. 80,151 shares of the stock traded hands. Oxford Immunotec Global PLC has a 12-month low of $9.49 and a 12-month high of $19.51. The stock has a 50-day moving average price of $16.83 and a 200 day moving average price of $15.21. The stock’s market cap is $363.68 million.
Oxford Immunotec Global PLC (NASDAQ:OXFD) last issued its earnings results on Tuesday, August 1st. The company reported ($0.32) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.32). The business had revenue of $26.10 million during the quarter, compared to the consensus estimate of $25.05 million. Oxford Immunotec Global PLC had a negative return on equity of 35.76% and a negative net margin of 34.58%. The firm’s revenue for the quarter was up 35.9% on a year-over-year basis. During the same period in the previous year, the company posted ($0.29) earnings per share. On average, analysts anticipate that Oxford Immunotec Global PLC will post ($1.63) earnings per share for the current fiscal year.
A number of analysts recently commented on the stock. Cowen and Company reaffirmed a “buy” rating and issued a $22.00 price target on shares of Oxford Immunotec Global PLC in a report on Thursday, August 3rd. Zacks Investment Research downgraded shares of Oxford Immunotec Global PLC from a “buy” rating to a “hold” rating in a research note on Wednesday, May 3rd. BTIG Research reissued a “buy” rating on shares of Oxford Immunotec Global PLC in a research note on Thursday, May 4th. ValuEngine raised shares of Oxford Immunotec Global PLC from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and set a $26.00 price target on shares of Oxford Immunotec Global PLC in a research report on Thursday, August 3rd. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $20.25.
In other Oxford Immunotec Global PLC news, VP Elizabeth M. Keiley sold 4,085 shares of the business’s stock in a transaction on Thursday, June 15th. The stock was sold at an average price of $15.01, for a total value of $61,315.85. Following the transaction, the vice president now owns 25,393 shares of the company’s stock, valued at $381,148.93. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, COO Peter Edwardson sold 22,371 shares of the business’s stock in a transaction on Monday, August 7th. The stock was sold at an average price of $17.70, for a total value of $395,966.70. Following the completion of the transaction, the chief operating officer now directly owns 102,644 shares in the company, valued at approximately $1,816,798.80. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 126,195 shares of company stock worth $2,073,682. 7.58% of the stock is owned by insiders.
About Oxford Immunotec Global PLC
Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.
Receive News & Stock Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related stocks with our FREE daily email newsletter.